Ge Long Hui·2026-01-30 11:17Group 1 - The company expects to record an unaudited net loss attributable to the parent company of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to an audited net profit of RMB 39.73 million in 2024 [1] - The company is actively advancing its R&D projects, with R&D expenditure accounting for an increasing proportion of revenue. The Phase III clinical trial for the FDA018 antibody-drug conjugate has exceeded its enrollment target, with over 350 cases enrolled [1] - The company’s subsidiary is supporting the industrialization of antibody-drug conjugates (ADC) by conducting commercial-scale production technology transfers and process validations [1] Group 2 - The company’s photodynamic drug development projects are progressing as planned, with the application for the registration of a powder for oral solution of Amifostine for intraoperative visualization of high-grade gliomas accepted [2] - The company’s R&D expenditure for the reporting period was approximately RMB 350 million [2] - The product Liposomal Doxorubicin was included in the national centralized procurement directory for the first time in 2024, leading to a corresponding adjustment in sales strategy and a decrease in profit contribution of approximately RMB 100 million compared to the same period last year [2]